Variable

TIL in residual disease

X²

High

Low

Age < 40 y

30 (49%)

27 (64%)

p.094

Clinical stage cTNM

IIa

21 (34.4%)

5 (11.9%)

p.002

IIb

23 (37.7%)

9 (21.4%)

IIIa

10 (16.4%)

10 (23.8%)

IIIb

1 (1.6%)

9 (21.4%)

IIIc

6 (9.8%)

9 (21.4%)

Histology

Ductal

39 (63.9%)

25 (60%)

p.473

Lobulillar

22 (36.1%)

17 (40%)

No DCIS in core biopsy

40 (65.6%)

31 (73.8%)

p.363

Grade 3

16 (26%)

11 (26%)

p.675

Nolymphovascular invasion

45 (73.8%)

35 (83.3%)

p.131

Ki67 < 50%

8 (16%)

4 (10%)

p.270

High TIL in core biopsy

54 (88.5%)

42 (100%)

p.022

NAC

Antracyclines + taxanes

55 (90%)

40 (95%)

p.254

Residual disease stagey pTNM

I

31 (50.8%)

6 (14.3%)

p.002

IIa

16 (26.2%)

9 (21.4%)

IIb

6 (9.8%)

6 (14.3%)

IIIa

6 (9.8%)

15 (35.7%)

IIIb

1 (1.6%)

0 (0%)

IIIc

1 (1.6%)

6 (14.3%)

Residual tumor

Multifocal

13 (21.3%)

10 (23.8%)

p.649

DCIS in residual disease

9 (14.8%)

9 (21.8%)

p.311

No LVI in residual disease

12 (19.7%)

16 (38.1%)

p.048

Breast conservative surgery (BCS)

34 (55.7%)

9 (22%)

p.001

Adjuvant RT

52 (85.2%)

40 (95.2%)

p.252